Paediatric formulations of second-line anti-tuberculosis medications: challenges and considerations-Reference-Cited by-同舟云学术

Paediatric formulations of second-line anti-tuberculosis medications: challenges and considerations

Published:2015-12-01 Issue:12 Volume:19 Page:61-68
ISSN:1027-3719
Container-title:The International Journal of Tuberculosis and Lung Disease
language:en
Short-container-title:int j tuberc lung dis

Author:

Taneja R.¹,Garcia-Prats A. J.²,Furin J.²,Maheshwari H. K.³

Affiliation:

1. The Global Alliance for TB Drug Development, New York, New York, USA

2. Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa

3. Macleods Pharmaceuticals Ltd, Mumbai, India

Publisher

International Union Against Tuberculosis and Lung Disease

Subject

Infectious Diseases,Pulmonary and Respiratory Medicine

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Manipulation of solid dosage forms for oral administration to paediatric patients for drug-resistant tuberculosis in South Africa: an observation study;BMC Pediatrics;2024-08-12

2. Acceptability of levofloxacin dispersible and non-dispersible tablet formulations in children receiving TB preventive treatment;IJTLD OPEN;2024-02-01

3. Stability of extemporaneously prepared clofazimine oral suspensions;Journal of Pharmacy Practice and Research;2024-01-17

4. Nanotechnological innovations in paediatric tuberculosis management: current trends and future prospects;Frontiers in Drug Delivery;2024-01-08

5. Development of low-cost, weight-adjustable clofazimine mini-tablets for treatment of tuberculosis in pediatrics;European Journal of Pharmaceutical Sciences;2023-08